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Abstract
Aims: Circulating endothelial progenitor cells (EPC), involved in endothelial regeneration, neovascularisation, and
determination of prognosis in cardiovascular disease can be characterised with functional assays or using
immunofluorescence and flow cytometry. Combinations of markers, including CD34+KDR+ or CD133+KDR+, are used.
This approach, however may not consider all characteristics of EPC. The lack of a standardised protocol with regards to
reagents and gating strategies may account for the widespread inter-laboratory variations in quantification of EPC. We,
therefore developed a novel protocol adapted from the standardised so-called ISHAGE protocol for enumeration of
haematopoietic stem cells to enable comparison of clinical and laboratory data.
Methods and Results: In 25 control subjects, 65 patients with coronary artery disease (CAD; 40 stable CAD, 25 acute
coronary syndrome/acute myocardial infarction (ACS)), EPC were quantified using the following approach: Whole blood was
incubated with CD45, KDR, and CD34. The ISHAGE sequential strategy was used, and finally, CD45
dimCD34
+ cells were
quantified for KDR. A minimum of 100 CD34
+ events were collected. For comparison, CD45
+CD34
+ and CD45
2CD34
+ were
analysed simultaneously. The number of CD45
dimCD34
+KDR
+ cells only were significantly higher in healthy controls
compared to patients with CAD or ACS (p=0.005 each, p,0.001 for trend). An inverse correlation of CD45
dimCD34
+KDR
+
with disease activity (r=20.475, p,0.001) was confirmed. Only CD45
dimCD34
+KDR
+ correlated inversely with the number of
diseased coronaries (r=20.344; p,0.005). In a second study, a 4-week de-novo treatment of atorvastatin in stable CAD
evoked an increase only of CD45
dimCD34
+KDR
+ EPC (p,0.05). CD45
+CD34
+KDR
+ and CD45
2CD34
+KDR
+ were indifferent
between the three groups.
Conclusion: Our newly established protocol adopted from the standardised ISHAGE protocol achieved higher accuracy in
EPC enumeration confirming previous findings with respect to the correlation of EPC with disease activity and the increase
of EPC during statin therapy. The data of this study show the CD45
dim fraction to harbour EPC.
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Introduction
In 1997, Asahara et al. [1] reported the isolation of putative
endothelial progenitor cells (EPC) from human peripheral blood on
the basis of cellsurfaceexpression of haematopoieticstem cell(CD34)
or kinase insertdomain receptor(KDR)markers.Theyobservedthat
these cells differentiate into endothelial cells in vitro and in vivo.
Circulating EPC correlate with risk factors for coronary artery
disease [2], participate in endothelial regeneration [3], and can be
characterised with functional assays [2,4] or immunofluorometric
methods such as flow cytometry. We and others have shown that
EPC independently predict future cardiovascular events in
patients at risk [5,6]. The use of defined culturing assays is
handicapped by difficulties in standardisation and the prolonged
assay time. Several combinations of markers have been employed
by us and other groups to assess circulating EPC [7,8]. Currently,
the combinations of CD133
+CD34
+KDR
+, CD34
+KDR
+,o r
CD14
+CD34
low [9,10,11], are widely used to define or select cells
that express properties attributed to EPC.
However,thelackofanestablishedandgenerallyacceptedmarker
combination and of a standardised protocol with regards to reagents
and gating strategies may account for the widespread interlaboratory
variations in quantification of EPC [12]. This hampers comparison
and cooperations between different laboratories.
We, therefore, developed a protocol adapted from the
standardised so-called ISHAGE (International Society of Hema-
totherapy and Graft Engineering) [13] protocol for enumeration of
haematopoetic stem cells to enable comparison of clinical and
laboratory data. Since recent studies suggest that particularly the
fraction of CD45
2 cells may harbour the ‘‘true’’ circulating EPCs
[14], we included the pan-leukocyte marker CD45 in the analysis.
Quantification was performed strictly following the sequential
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e13790gating strategy [13] and CD34
+ cells were additionally subdivided
in CD45
2, CD45
ldim and CD45
bright subpopulations.
Materials and Methods
Patients and control subjects
The study population comprised 27 control subjects and 70
patients with coronary artery disease recruited in two centres.
Twentyseven healthy subjects without any evidence of CAD by
history and physical examination served as a control group. Forty
patients had stable coronary artery disease (CAD), defined as
angiographically documented CAD and the absence of acute
coronary syndromes (ACS) for 3 months before blood samples
were drawn. Thirty patients were studied with unstable CAD
defined as de novo angina, crescendo angina, or angina at rest.
Patients with ACS were further stratified for troponin T positivity
to account for potential effects of myocardial necrosis on EPC
levels. Time to first and time to the last onset of symptoms,
repetitive angina, and as well as duration of symptoms were
assessed. Extent of disease was quantified in all patients by the
number of coronary arteries affected. Inclusion criteria were age
from 18 to 85 years, signed written informed consent, documented
CAD for patients with stable CAD or ACS (Braunwald IIIB) or
acute myocardial infarction (both non–ST-segment and ST-
segment myocardial infarction). Exclusion criteria were clinical
or biochemical evidence for the presence of concomitant
inflammatory disease, chronic renal insufficiency (serum crea-
tinine ,1.4 mmol/L), impaired left ventricular ejection fraction
(,45%), autoimmune or malignant disease, thrombocytopaenia
(,100 000/L), anaemia (haemoglobin ,8.5 g/dL), inability to
understand the consent form, participation in or consent to
participate in another study, previous coronary bypass surgery,
severe peripheral arterial occlusive disease, or atrial fibrillation.
A subgroup of ten patients with angiographically documented
stable angina, who had not previously taken statins were included
into a second study. Here, all patients received a de-novo therapy
of 40 mg atorvastatin per day. Exclusion criteria were previous
treatment with a statin, acute coronary syndromes in the last 4
weeks, or any of the above mentioned exclusion criteria.
All study participants gave written informed consent, and the
study was approved by the ethics committee of J.W.Goethe
University (Frankfurt, Germany).
Definition of Risk Factors for Coronary Artery Disease
Risk factors were defined as follows: Hypertension was defined
as a history of hypertension for .1 year requiring the initiation of
antihypertensive therapy by the primary physician, or a repetitive
measurement of hypertensive resting blood pressure. Smoking was
defined as a history of smoking for .2 pack-years and/or smoking
in the last year. Positive family history for coronary artery disease
was defined as documented evidence of premature coronary artery
disease in a close relative (men ,55 and women ,65 years of age)
[15]. Diabetes mellitus was defined as the need for oral
antidiabetic drug therapy or insulin use. We calculated a score
giving the risk of an individual subject to develop cardiovascular
disease by considering age .65 years, male sex, hypertension,
diabetes, smoking, and positive family history for coronary artery
disease as single cardiovascular risk factors [16].
Flow cytometry quantification of EPC, following the
ISHAGE (International Society for Hematotherapy and
Graft Engineering) gating strategy
EPC were quantified using the following approach: EDTA
collection tubes were transported on wet ice into the laboratory
and proceeded within 2 to 3 hours. FcR-blocking was added and
incubated for 10 minutes. All staining procedures were performed
on ice. 1 ml of whole blood was incubated with 4 ml of CD45
(FITC; Beckton Dickinson), 8 ml of KDR (PE; R&D Systems, cat
no. FAB 3578), and 4 ml of CD34 (PerCP; Beckton Dickinson).
The samples were lysed before flow cytometry analysis. The
ISHAGE sequential strategy [17] was used (see Figure 1).
An initial gate (R1 plot 1) is set on a CD45 vs. side scatter (SSC)
dot plot to contain all CD45
+ events including CD45
dim and
CD45
bright. This will exclude CD45
2 events (i.e. red blood cells,
platelets and other debris). The lower limit of CD45 expression is
adapted from a CD34 vs. CD45 histogram performed on ungated
data (plot 5). R1 also contains a gate R4, which defines
lymphocytes as CD45
brightSSC
low cells.
The events in gate R1 are then displayed on a CD34 vs. SSC
dot plot (plot 2) and a second gate (R2) is produced to include the
cluster of CD34
+ events. The third plot (plot 3) is obtained by
plotting the events that fulfil the criteria of gates R1 and R2 (i.e.
sequential gating). Cells forming a cluster of blasts with charac-
teristic low SSC and low CD45 fluorescence (SSC
lowCD45
dim
cells) are then gated on this third plot to produce a third region
(R3) (plot 3). To differentiate between CD45
dim and CD45
bright
cells, the right margin of the CD34
+ cells in plot 5 serves as cut-off.
At this step, the gating strategy has defined CD34
+CD45
dim cells.
In case, CD45
bright cells were investigated for comparison, gate R3
was shifted to the right population visible in plot 3. Finally, the
events fulfilling the criteria of all three gates (R1, R2 and R3) are
then displayed on a forward light scatter (FSC) vs. SSC dot plot to
confirm that the selected blasts fall into the lymphocyte region (R5)
(plot 4). The lymphocyte region (plot 6) was adjusted from a SSC
vs. FSC plot gated on lymphocytes from R4 (plot 1), employing
only small lymphocytes (FSC
low, R5 in plot 6).
CD45
dimCD34
+KDR
+ endothelial progenitor cells are then de-
ductedfromthe upperrightquadrantofplot7, defining CD34
+KDR
+
cells, when falling into all three regions (R2, R3 and R5).
Isotype controls are not required because the gating strategy
excludes cells that non-specifically bind anti-CD34. CD45
dimCD-
34
+KDR
+ cell determinations are performed in duplicate and the
mean CD45
dimCD34
+KDR
+ value is used. Similarly CD45
2CD34
+,
or CD45
brightCD34
+ cells were quantified for KDR expression.
Around 250,000 events in the gate R1 were acquired (approxi-
mately 290,000 total events), and a minimum of 100 CD34
+ events
were collected, according to recommendations. Intraindividual
correlation was r=0.92 (p,0.001) and inter-class correlation was
r=0.93 (p,0.001) for CD45
dimCD34
+KDR
+, and thus comparable
to our previously published data (r=0.86, p,0.001) [5].
Statistical analysis
Continuous variables were tested for normal distribution with
the Kolmogorov-Smirnov test. Comparisons between the two
groups were analysed by t test (two-sided) for normally distributed
variables or ANOVA for normally distributed variables with more
than two subgroups, and by the Kruskal-Wallis test for non-
normally distributed variables. Post hoc range tests and pair-wise
multiple comparisons were performed with the t test (two-sided)
with LSD adjustment. Not normally distributed continuous
variables (CD45
dimKDR
+CD34
+ EPC, HDL cholesterol) were
compared by the Mann-Whitney-U test. Comparison of categor-
ical variables was generated by the Pearson x
2 test. Data are
expressed as mean 6 SD, unless otherwise stated. Multivariate
linear regression analysis and nonparametric bivariate correlation
(Spearman rank correlation coefficient) were used to correlate
circulating EPC counts with cardiovascular risk factors. To
identify independent determinants of EPC numbers, a multivariate
Quantification of EPC
PLoS ONE | www.plosone.org 2 November 2010 | Volume 5 | Issue 11 | e13790Figure 1. Flow cytometry quantification of EPC following the ISHAGE (International Society for Hematotherapy and Graft
Engineering) gating strategy (see Methods section).
doi:10.1371/journal.pone.0013790.g001
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was performed. Statistical significance was assumed, if a null
hypothesis could be rejected at p#0.05. All statistical analysis was
performed with SPSS 16 (SPSS Inc.).
Results
Patient Characteristics
The baseline characteristics of the 97 subjects are summarised
in Table 1. As expected, patients with documented coronary
artery disease had a significantly higher number of risk factors,
were significantly older, and more frequently were treated with
statins, platelet inhibitors, and ACE inhibitors/AT-1 receptor
blockers. Due to the intensive statin treatment in patients with
CAD, LDL-cholesterol was significantly lower compared to
controls. In addition, patients with ACS were less likely to be
treated with statins, antithrombotics, and ACE inhibitors/AT-1
receptor blockers compared to patients with stable CAD prior to
inclusion into the study.
The subgroup of ten patients with stable CAD included in the
second study, had a similar cardiovascular risk profile, age,
number of diseased coronaries, and cardiovascular drugs, with the
exception of statins, compared to the total group of stable CAD.
Circulating endothelial progenitor cells
There were significantly higher numbers of CD45
dimCD-
34
+KDR
+ in controls compared to CAD (0.016760.0178% vs.
0.00486 [18] 0.0037%/leukocytes, p,0.001) or ACS (0.0071%-
60.0067%/leukocytes, p,0.005; with p,0.001 for trend)
(Figure 2A). In contrast to our previous findings [5], patients with
ACS did not have lower numbers of circulating progenitors. To
assess potential confounders due to ischaemia-induced mobilisation,
we subdivided the group of ACS according to the presence of
troponin T. Indeed, patients with cardiac necrosis had a strong
tendency towards increased numbers of CD45
dimCD34
+KDR
+-cells
(p,0.08; Figure 2B). Among patients with ACS, there was an evident
tendency (r=0.37, p,0.07) towards increased number of
CD45
dimCD34
+KDR
+-cells with time of first angina, but not with
duration of pain or time to last angina. Moreover, CD45
dimCD-
34
+KDR
+-cells correlated inversely with the number of diseased
coronary arteries (r=20.28; p,0.01; Figure 2C) and with the
number of individual cardiovascular risk factors (r=20.35, p,0.001;
Figure 2D). On multivariate analysis, including LVEF (r=20.28,
p,0.01), number of diseased coronaries, disease activity and
cardiovascular risk factors, number of cardiovascular risk factor
remained the only significant determinant for number of
CD45
dimCD34
+KDR
+-cells(t=22.44, p,0.05, p,0.001 for trend).
On the other hand, CD45
brightCD34
+KDR
+ (control:
0.009760.008%, CAD: 0.00660.006%, ACS: 0.00660.004%),
or CD45
negCD34
+KDR
+ (control: 0.00560.003%, CAD:
0.00860.008%, ACS: 0.00760.0068%) did not differ between
controls and patients with CAD or ACS, nor was there any
correlation with diseased coronaries (data not shown).
Effects of treatment with atorvastatin on levels of
circulating endothelial cells
In order to assess a potential treatment effect on EPC numbers,
10 patients with stable CAD were treated de-novo with 40 mg of
atorvastatin for 4 weeks. As illustrated in Figure 3, statin treatment
significantly increased numbers of CD45
dimCD34
+KDR
+ 2.6-fold
(p=0.047), whereas CD45
2CD34
+KDR
+ and CD45
brightCD-
34
+KDR
+ cells did not change (data not shown).
Discussion
Undoubtedly, there is a large body of evidencefor the regenerative
potential of endothelial progenitor cells since their discovery in 1997
[18,19,20]. Since then, it has been uniformly shown that numbers of
circulating EPC in humans show an inverse association with
atherosclerosis [20] and cardiovascular risk [21] and ultimately,
independently predict cardiovascular disease progression [5,6].
Commonly, surface marker combinations include markers for HSC
Table 1. Patients baseline characteristics.
Control Stable CAD ACS P
N2 7 4 0 3 0
Age (years) 53614 61611 61613 Co vs CAD and ACS: ,0.05
Male gender 18 (67%) 40 (100%) 25 (83%) Co vs CAD: p,0.05
CVRF score 1.561.2 3.561.2 3.061.1 Co vs CAD and ACS: ,0.001
Hypertension 8 (14%) 31 (77%) 19 (63%) Co vs CAD and ACS: ,0.05
Smoking 4 (15%) 12 (30%) 13 (43%) n.s.
Diabetes mellitus 1 (4%) 11 (27%) 8 (27%) Co vs CAD and ACS: ,0.05
Family history 5 (19%) 13 (33%) 4 (13%) n.s.
Troponin T positive n.a n. a. 9 (30%) n. a.
Total cholesterol 194645 182640 195640 n.s.
LDL cholesterol 90640 49614 75640 Co vs CAD: ,0.05
HDL cholesterol 82640 102637 89650
Extent of disease
(1-/2-/3 vessel disease)
0 1.960.9
17/10/13
2.060.9
11/9/10
Co vs CAD and ACS: ,0.0001
Statin therapy 4 (15%) 24 (60%) 7 (24%) CAD vs. Co and ACS: ,0.05
Aspirin/Clopidogrel 2 (7%) 35 (88%) 11 (38%) CAD vs. Co and ACS: ,0.001
ACE-Inhibitor/AT1-Blocker 5 (19%) 34 (85%) 14 (48%) CAD vs. Co and ACS: ,0.005
CVRF: cardiovascular risk factor score; Patients baseline characteristics for patients with ACS with troponin positive or negative values are similar.
doi:10.1371/journal.pone.0013790.t001
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endothelial marker KDR (VEGFR-2). For quantification of
circulating EPC in humans, flow cytometry is widely used.
Nevertheless, there are ongoing debates about the definition of
‘true’ EPC, as well as the availability of a reliable method to assess
their quantity and quality, functional status, and therapeutic
Figure 2. Percentage of circulating CD45
dimCD34
+KDR
+ CPC/leukocytes. (A) in healthy control subjects and patients with stable CAD and ACS.
Bars represent mean with SE. (B) in healthy control subjects and patients with stable CAD, troponin T negative (TTneg) ACS and troponin positive (TTpos) ACS.
Significance levels on bars represent differences between groups; Significance level for the whole analysis is given above. (C) Correlation of CD45
dimCD34
+KDR
+
CPC/leucocytes with the number of diseased (stenosis.50%) coronaries in healthy control subjects and patients with stable CAD and ACS. (D) Correlation of
CD45
dimCD34
+KDR
+CPC/leucocytes with the number of individual cardiovascular risk factors in healthy control subjects and patients with stable CAD and ACS.
doi:10.1371/journal.pone.0013790.g002
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derived circulating progenitor cells, presumably of haematopoietic
origin without the ability of differentiating into mature endothe-
lium have an important role in vascular homoeostasis. These cells
are found in cell fractions staining positive for CD34 and
CD34
+KDR
+ Generally, to assess CPC function and numbers in
humans, there are numerous protocols in different laboratories for
culture assays and immunostaining with surface markers. So far,
no consensus for a standardised protocol has been reached
amongst laboratories that would allow interlaboratory compara-
bility and reproducibility. The use of defined culturing assays is
handicapped by difficulties in standardisation and the prolonged
assay time. Definition of CPC with angiogenetic potential by
surface markers is challenging, given the change in surface marker
profiles during the process of mobilisation and maturation.
Consequently, most groups use combination of surface markers.
But even then, gating strategies are not standardised. Furthermore,
the variability associated with enumeration of low-frequency cells
(i.e., as low as 0.1% or 5 cells/ml) is exceedingly large [22].
About a decade ago, the need for a rapid and reliable marker for
the engraftment potential of haematopoietic stem and progenitor
cell (HSC) transplants has led to the development of flow cytometric
assays to quantitate such cells on the basis of their expression of
CD34 [13]. The standardisation was based on the use of state-of-
the-art bright fluorochrome conjugates and the combination of the
HSC marker CD34 with CD45 counterstaining. Moreover, gating
strategies to separate the CD34
+ HSC from irrelevant cell
populations, as well as inclusion of CD34
dim and CD34
bright
populations were established. Omission of the negative control
staining was introduced to facilitate routine flow cytometric
measurements. Lastly, it has been agreed to enumerate at least
100 CD34
+ cells to ensure a 10% precision [22]. During the last
decade, the ISHAGE (International Society of Hematotherapy and
Graft Engineering) method to detect CD34 HSC in haematological
studies has been successfully implemented in multicenter trials [23].
We, therefore, developed a new protocol adapted from the
standardised ISHAGE) [13] protocol for enumeration of haema-
topoietic stem cells to enable comparison of clinical and laboratory
data. The sequential strategy for quantification was strictly
followed. We added the PE-labelled surface marker KDR to the
original protocol. After identification of HSC, immunofluores-
cence of these cells for KDR was assessed.
Using this protocol, we achieved a high intra- and interclass
accuracy. The standardisation of the protocol allowed differently
experienced investigators to reproducibly analyse the measurements.
The data obtained with this protocol showed only numbers of
CD45
dimCD34
+KDR
+ cells to be significantly higher in healthy
controls compared to patients with CAD or ACS. CD45
dimCD-
34
+KDR
+ correlated inversely with the number of cardiovascular
risk factors, even after correction for disease activity and number
of diseased coronaries. Apart from the finding of an increase of
CPC in patients with myocardial infarction, these findings are well
in line with our previously published data [5]. We ascribe this to
ischaemia-induced mobilisation in these patients. Confirming our
previous results, the 4-week de-novo treatment of atorvastatin in
stable CAD evoked an increase only of CD45
dimCD34
+KDR
+
EPC, confirming our previous study [24]. We thereby confirm that
indeed only the fraction of CD45
dim cells harbours the ‘‘true’’
circulating EPCs [14].
In conclusion, the protocol adapted from the standardised
ISHAGE protocol demonstrated a higher accuracy in detecting
subsets of EPCs. This valid, rapid and easy to use quantification of
EPC in clinical studies may be suitable to overcome interlabora-
tory discrepancies. Stratification with respect to the expression of
CD45 indicates that specifically the CD45
dimCD34
+KDR
+ cell
population correlates with cardiovascular disease and is signifi-
cantly regulated by statin treatment, suggesting that the CD45
dim
fraction contains the prognostic relevant EPC populations.
Therefore, future studies should prospectively address, whether
the detection of CD45
dimCD34
+KDR
+ cells is only useful as
biomarker or whether this population of circulating cells indeed
comprise cells with a high capacity for vascular repair.
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